3D Systems Announces Breakthrough in Bioprinting Technology and Expansion of Regenerative Medicine Initiative

Nachrichtenquelle: globenewswire
27.01.2021, 14:30  |  512   |   |   

  • Demonstration of high rate, micron-level printing capability enabling vascularization required to sustain living cells
  • Critical technology elements reach level required to dramatically expand application opportunities in human body
  • Pathway for accelerated new drug therapy development and reduced need for animal testing through bioprinted cellular in vitro laboratory tools
  • Company expanding investment in 2021 to commercialize targeted applications and accelerate long term, profitable growth in healthcare

ROCK HILL, S.C., Jan. 27, 2021 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) today announced its decision to significantly expand its development efforts focused on regenerative medicine and bioprinting solutions. This decision was driven by the tremendous progress made in collaboration with United Therapeutics Corporation (NASDAQ:UTHR) and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, on the development of 3D printing systems for solid-organ scaffolds. Leveraging this work as well as accomplishments with additional partners, 3D Systems intends to invest, further develop, and commercialize solutions for the diverse application opportunities in regenerative medicine, including the development of non-solid organ applications requiring biologically sustainable vasculature.

In 2020, 3D Systems and United Therapeutics achieved significant progress in the development of a next-generation additive manufacturing platform solution for lung scaffolds that is capable of full size, vascularized, rapid, micron-level printing. 3D Systems’ capabilities as a technology innovator, spanning hardware, software, and materials science, combined with United Therapeutics’ renowned expertise in regenerative medicine has enabled advances in lung modeling, 3D printing, as well as material formulation using a unique rhCollagen, and material handling to yield significant capabilities in bioprinters and biomaterials for lung manufacturing. As a result, 3D Systems has built a portfolio of unique capabilities specifically designed to address the requirements of regenerative medicine applications. The newly developed Print to Perfusion process enables 3D printing of high-resolution scaffolds which can be perfused with living cells to create tissues. The ability to print large, vascularized, highly detailed hydrogel scaffolds at rapid speeds is now opening new opportunities for a range of tissue applications. To advance these efforts, 3D Systems is expanding its high-speed Figure 4 technology through innovation tailored to bioprinting and regenerative medicine. Building upon these capabilities, the company – in collaboration with its partners – will be able to advance innovation into numerous applications within the human body. The company also believes these capabilities have the potential to enable novel laboratory testing methods to accelerate the development of new drug therapies while reducing the need for animal testing.

Seite 1 von 4


Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

3D Systems Announces Breakthrough in Bioprinting Technology and Expansion of Regenerative Medicine Initiative Demonstration of high rate, micron-level printing capability enabling vascularization required to sustain living cellsCritical technology elements reach level required to dramatically expand application opportunities in human bodyPathway for …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

COMMUNITY

ZeitTitel
05.03.21